Agree re GVAX being easier to prepare, I just don't believe it will be as effective. DNDN went through the quality control issue in 2002, when the FDA halted all of the ongoing cancer vaccine trials in the US. Sort of a training run for the manufacturing arm of the company, and they have said several times since that the process was invaluable. We'll see.
Market Data 
Markets 
AI
